In this episode of The HemOnc Pulse, Amer Zeidan, MBBS, MHS, of Yale, discusses the impact of AML classification updates, the practical implications of testing for genetic alterations, and how patient characteristics inform his approach to treating AML, with host Chadi Nabhan, MD, MBA, FACP.

Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost-effectiveness of pola-R-CHP in previously untreated DLBCL.

In the latest episode of The HemOnc Pulse, Graham Collins, MBBS, MA, MRCP, FRCPath, DPhil, a lymphoma specialist at Oxford Cancer and Haematology Centre, discusses the findings from the HoLISTIC Consortium, and what he thinks about checkpoint inhibitors upfront in the treatment of Hodgkin lymphoma.

What is it about chimeric antigen receptor (CAR) T-cell therapies in hematologic oncology that keeps Michael Bishop, MD, Director of the Hematopoietic Stem Cell Transplantation Program at the University of Chicago, awake at night? In the latest episode of the podcast, Dr. Bishop discusses the matter and speaks about research that is identifying why CAR T-cell therapy doesn't always work.

In the latest episode of The HemOnc Pulse, Laurie H. Sehn, MD, MPH, Chair of the Lymphoma Tumour Group at the BC Cancer Centre for Lymphoid Cancer, talks with host Chadi Nabhan, MD, MBA, FACP, about which bispecific antibodies will change the game in follicular lymphoma treatment. Dr. Sehn also explains why the TRIANGLE study is anticipated to be practice-changing and how it may make upfront transplant obsolete in MCL.

Sanam Loghavi, MD, stops by The HemOnc Pulse and chats with host Chadi Nabhan, MD, MBA, FACP, about why she thinks 2022 was a major year for MDS in this latest episode of the podcast. With the unveiling of the two new MDS classification systems in the past year, Dr. Loghavi breaks down the classification models and what it means for the specialty.

In the latest episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Elizabeth Brem, MD, Clinical Associate Professor in the School of Medicine at the University of California, Irvine, off the heels of the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition. Dr. Brem discusses which chronic lymphocytic leukemia (CLL) abstracts from ASH 2022 cannot be ignored, the latest news in Richter’s transformation, and why she is moving away from ibrutinib in her own clinical practice.

Ruben Mesa, MD, President and Executive Director of the Atrium Health cancer service line (formerly the Executive Director of Mays Cancer Center), discusses his long career in myeloproliferative neoplasms (MPNs), the evolution of the disease, and what abstracts caught his attention at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.

In the inaugural episode of The HemOnc Pulse, podcast host Chadi Nabhan, MD, MBA, FACP, talks with Hagop Kantarjian, MD, and Elias Jabbour, MD, both of the Department of Leukemia at the University of Texas MD Anderson Cancer Center. The trio cover high-impact studies, novel treatment strategies, and controversial standard-of-care approaches for AML as well as ALL that were presented at the 2022 American Society of Hematology Annual Meeting & Exposition.